Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2025-12-25 @ 9:10 PM
Study NCT ID:
NCT07185256
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-07-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
Sponsor:
Opus Genetics, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-25
Start Date Type:
ACTUAL
Primary Completion Date:
2030-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-08
Completion Date Type:
ESTIMATED
First Submit Date:
2025-07-17
First Submit QC Date:
None
Study First Post Date:
2025-09-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-11
Last Update Post Date:
2025-12-17
Last Update Post Date Type:
ESTIMATED